Page last updated: 2024-11-05

vanadates

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

Vanadates: Oxyvanadium ions in various states of oxidation. They act primarily as ion transport inhibitors due to their inhibition of Na(+)-, K(+)-, and Ca(+)-ATPase transport systems. They also have insulin-like action, positive inotropic action on cardiac ventricular muscle, and other metabolic effects. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

vanadate(3-) : A vanadium oxoanion that is a trianion with formula VO4 in which the vanadium is in the +5 oxidation state and is attached to four oxygen atoms. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID61672
CHEMBL ID179166
CHEBI ID46442
MeSH IDM0022514

Synonyms (18)

Synonym
vanadium (v) tetraoxide
vo4(3+)
ortho-vanadate
14333-18-7
vanadate(3-)
tetraoxovanadate(3-)
tetraoxidovanadate(3-)
CHEBI:46442 ,
vo4(3-)
[vo4](3-)
tetraoxovanadate(v)
tetraoxovanadate
vanadates
trioxido(oxo)vanadium
CHEMBL179166 ,
bdbm50391109
AB01566832_01
Q27104568

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"Although it has been reported that vanadate is effective in diminishing the expression of diabetes in the rat, the severe toxic side effects noted in the vanadate-treated animals suggest that chronic oral administration of vanadate argues against its use in human diabetes."( Tiron administration minimizes the toxicity of vanadate but not its insulin mimetic properties in diabetic rats.
Domingo, JL; Gomez, M; Keen, CL; Llobet, JM; Sanchez, DJ, 1992
)
0.28
" Although these compounds are very toxic in V79 cells, no mutagenic effect was observed in the presence or in the absence of S9 fraction."( Genotoxicity of vanadium compounds in yeast and cultured mammalian cells.
Bronzetti, G; Del Carratore, R; Della Croce, C; Fiorio, R; Galli, A; Giromini, L; Morichetti, E; Rosellini, D; Vellosi, R, 1991
)
0.28
" Embryolethality and teratogenicity were not observed at maternally toxic doses and below, but fetal toxicity was evidenced by a significant delay in the ossification process of some skeletal districts at 30 mg/kg/d."( Developmental toxicity evaluation of orthovanadate in the mouse.
Corbella, J; Domingo, JL; Ortega, A; Sanchez, D, 1991
)
0.28
" In isolated perfused livers from fasted rats, sodium orthovanadate (2 mmol/l) led to toxic responses including reduction of oxygen consumption, release of cytosolic (glutamate-pyruvate-transaminase (GPT) and lactate dehydrogenase (LDH)) and mitochondrial (glutamate-dehydrogenase (GLDH)) enzymes, intracellular accumulation of calcium, a marked depletion of glutathione (GSH) and an enhanced formation and release of thiobarbituric acid- (TBA) reactive material."( Effect of antioxidants on vanadate-induced toxicity towards isolated perfused rat livers.
Kayser, E; Strubelt, O; Younes, M, 1991
)
0.28
"The toxic potential of sodium orthovanadate towards isolated perfused rat livers was investigated at a dose of 2 mmol/l."( Vanadate-induced toxicity towards isolated perfused rat livers: the role of lipid peroxidation.
Strubelt, O; Younes, M, 1991
)
0.28
" The initial daily dosage of 100 mg elemental vanadium was increased by 50 mg at 2-d intervals for an assessment not only of the toxic effects, but also to determined the amount that caused a decline in feed intake to 25% of that of control animals."( Vanadium metabolism in sheep. I. Comparative and acute toxicity of vanadium compounds in sheep.
Ammerman, CB; Hansard, SL; Henry, PR; Simpson, CF, 1982
)
0.26
" The no observed adverse effect level (NOAEL) was 40 mg/kg per day."( Reproductive toxicity evaluation of vanadium in male mice.
Colomina, MT; Corbella, J; Domingo, JL; Llobet, JM; Sirvent, JJ, 1993
)
0.29
" Interest for vanadium and their compounds is because its toxic effects and uses in some biomedical areas: such as antineoplastic, cholesterol and glucose level blood, diuretic, oxygen haemoglobin affinity."( [Genotoxic effects of vanadium compounds].
Altamirano-Lozano, M, 1998
)
0.3
" However, it has severe toxic effects in both animal and man."( The mitogen-activated protein kinase pathway contributes to vanadate toxicity in vascular smooth muscle cells.
Chamberlain, NL; Clowes, AW; Daum, G; Levkau, B; Wang, Y, 1998
)
0.3
" Significant age-differences were found in most of the parameters used as indicators of nephrotoxicity in young and adult rats, with adverse renal effects being more severe with age."( Effect of age on vanadium nephrotoxicity in rats.
Corbella, J; de la Torre, A; Domingo, JL; Granero, S; Mayayo, E, 1999
)
0.3
" The pentavalent form is the most stable and toxic form of the element."( Assessment of the in vivo genotoxicity of vanadate: analysis of micronuclei and DNA damage induced in mice by oral exposure.
Cordelli, E; Crebelli, R; Leopardi, P; Siniscalchi, E; Veschetti, E; Villani, P, 2005
)
0.33
" It is concluded that V10 inhibits mitochondrial oxygen consumption and induces membrane depolarization more strongly than V1, pointing out that mitochondria is a toxicological target for V10 and the importance to take into account the contribution of V10 to the vanadate toxic effects."( Mitochondria as a target for decavanadate toxicity in Sparus aurata heart.
Aureliano, M; Gutiérrez-Merino, C; Soares, SS, 2007
)
0.34
" Our data suggest that zinc and selenium, in the concentrations mentioned above, provide no protection against adverse actions induced by sodium metavanadate at concentration levels of 50, 100 and 200 microM."( Preliminary studies on the effect of zinc and selenium on vanadium-induced cytotoxicity in vitro.
Zaporowska, H; Zwolak, I, 2009
)
0.35
"Vanadium can induce potent hypoglycemic effects in type 1 and type 2 diabetes mellitus animals, but toxic adverse effects have inhibited the translation of these findings."( A tea/vanadate decoction delivered orally over 14 months to diabetic rats induces long-term glycemic stability without organ toxicity.
Aguilar, F; Clark, TA; Edel, AL; Heyliger, CE; Junaid, A; Kim, HK; Kopilas, M; Merchant, M; Pierce, GN; Smyth, DD; Thliveris, JA, 2012
)
0.38
"4 μM), while both are less toxic in the dark."( Remarkable photocytotoxicity of curcumin in HeLa cells in visible light and arresting its degradation on oxovanadium(IV) complex formation.
Banerjee, S; Chakravarty, AR; Hussain, A; Khan, I; Kondaiah, P; Prasad, P, 2012
)
0.38
" Induction of oxidative stress in normal host cells is thought to be responsible for these adverse effects."( Prevention of myelosuppression and genotoxicity induced by cisplatin in murine bone marrow cells: effect of an organovanadium compound vanadium(III)-l-cysteine.
Basu, A; Bhattacharjee, A; Bhattacharya, S; Ghosh, P; Patra, AR, 2015
)
0.42
"The purpose of this study was to define the toxic effects of vanadium on thymic development in broilers fed on diets supplemented with 0, 5, 15, 30, 45 and 60 mg/kg of vanadium for 42 days."( Vanadium toxicity in the thymic development.
Cui, H; Cui, W; Guo, H, 2015
)
0.42
" Adverse events (AEs) were generally mild to moderate, with no AE-driven study drug discontinuations noted."( Pharmacokinetics, Pharmacodynamics, and Safety of Entospletinib, a Novel pSYK Inhibitor, Following Single and Multiple Oral Dosing in Healthy Volunteers.
Di Paolo, JA; Jin, F; Kearney, BP; Ramanathan, S; Robeson, M; Shao, L; Sharma, S, 2017
)
0.46
" But, the therapeutic outcome of CDDP therapy is limited due to its adverse effects including myelotoxicity and DNA damage which may lead to the subsequent risk of developing secondary cancer."( An oxovanadium(IV) complex protects murine bone marrow cells against cisplatin-induced myelotoxicity and DNA damage.
Basu, A; Bhattacharjee, A; Bhattacharya, S; Samanta, A, 2017
)
0.46
"Various NMDA-receptor antagonists have been investigated for their therapeutic potential in Alzheimer's disease with memantine shown to be safe and with relative efficacy."( Novel NMDA-receptor antagonists ameliorate vanadium neurotoxicity.
Adejare, A; Dybek, MB; Elufioye, TO; Folarin, OR; Ladagu, AD; Olopade, FE; Olopade, JO; Wallach, JV, 2020
)
0.56

Pharmacokinetics

ExcerptReferenceRelevance
" Pharmacokinetic analyses indicated that total and biliary clearances of rose bengal were increased in diabetic rats and that orthovanadate did not reverse these changes."( Effect of sodium orthovanadate on the hepatobiliary clearance of rose bengal in streptozotocin-induced diabetic rats.
Bauman, ME; Beaty, TM; Watkins, JB, 1993
)
0.29
" To develop clinically useful insulin-mimetic vanadyl complexes, clarification of the pharmacokinetic features of vanadyl compounds is essential."( Pharmacokinetic study on gastrointestinal absorption of insulinomimetic vanadyl complexes in rats by ESR spectroscopy.
Fugono, J; Sakurai, H; Yasui, H, 2001
)
0.31
" Pharmacokinetic analysis demonstrated that these capsules enhance the bioavailability of pharmacologically active vanadyl species."( Pharmacokinetic study and trial for preparation of enteric-coated capsule containing insulinomimetic vanadyl compounds: implications for clinical use.
Fugono, J; Sakurai, H; Yasui, H, 2004
)
0.32
" Pharmacokinetic investigation was performed using non-diabetic rats."( The anti-diabetic effects and pharmacokinetic profiles of bis(maltolato)oxovanadium in non-diabetic and diabetic rats.
Chen, GH; Lu, WL; Zhang, Q; Zhang, SQ; Zhong, XY, 2008
)
0.35
" Entospletinib displayed a median plasma half-life of 9-15 h; entospletinib exposures reached a plateau at ≥600 mg twice daily (likely due to solubility-limited absorption) and provided >90% CD63 inhibition at peak concentrations and >60% inhibition at trough concentrations (corresponding pSYK inhibition of >70 and >50%)."( Pharmacokinetics, Pharmacodynamics, and Safety of Entospletinib, a Novel pSYK Inhibitor, Following Single and Multiple Oral Dosing in Healthy Volunteers.
Di Paolo, JA; Jin, F; Kearney, BP; Ramanathan, S; Robeson, M; Shao, L; Sharma, S, 2017
)
0.46

Compound-Compound Interactions

ExcerptReferenceRelevance
" We used low doses of vanadate in combination with Trigonella foenum graecum seed powder (TSP) and evaluated their effect on the enzyme changes in diabetic rats."( Lower doses of vanadate in combination with trigonella restore altered carbohydrate metabolism and antioxidant status in alloxan-diabetic rats.
Bamezai, RN; Baquer, NZ; Basir, SF; Mohamad, S; Mohammad, S; Taha, A, 2004
)
0.32
"Lower doses of vanadate could be used in combination with TSP to effectively counter diabetic alterations without any toxic side effects."( Lower doses of vanadate in combination with trigonella restore altered carbohydrate metabolism and antioxidant status in alloxan-diabetic rats.
Bamezai, RN; Baquer, NZ; Basir, SF; Mohamad, S; Mohammad, S; Taha, A, 2004
)
0.32
" We evaluated the therapeutic potential of sodium vanadate combined with a vanadium detoxification agent, L-ascorbic acid, in a SMA mouse model."( Sodium vanadate combined with L-ascorbic acid delays disease progression, enhances motor performance, and ameliorates muscle atrophy and weakness in mice with spinal muscular atrophy.
Hsieh-Li, HM; Li, H; Lin-Chao, S; Liu, HC; Ting, CH; Tsai, LK; Wen, HL, 2013
)
0.39
"Sodium vanadate (200 μM), L-ascorbic acid (400 μM), or sodium vanadate combined with L-ascorbic acid (combined treatment) were applied to motor neuron-like NSC34 cells and fibroblasts derived from a healthy donor and a type II SMA patient to evaluate the cellular viability and the efficacy of each treatment in vitro."( Sodium vanadate combined with L-ascorbic acid delays disease progression, enhances motor performance, and ameliorates muscle atrophy and weakness in mice with spinal muscular atrophy.
Hsieh-Li, HM; Li, H; Lin-Chao, S; Liu, HC; Ting, CH; Tsai, LK; Wen, HL, 2013
)
0.39
"Transporter-mediated drug-drug interactions (DDI) may induce adverse clinical events."( Inhibition and stimulation of the human breast cancer resistance protein as in vitro predictor of drug-drug interactions of drugs of abuse.
Maurer, HH; Meyer, MR; Wagmann, L, 2018
)
0.48

Bioavailability

ExcerptReferenceRelevance
" It eliminated hyperglycemia and restored the normal rate of absorption of AIB and 3-o-methyl glucose by the intestine."( Reversal by vanadate of the effect of diabetes on intestinal growth and transport.
Dobish, MP; Hajjar, JJ; Tomicic, TK, 1989
)
0.28
" Citrate alone is poorly absorbed by symbiosomes; this uptake is greatly enhanced by addition of iron."( Uptake of iron by symbiosomes and bacteroids from soybean nodules.
Meyer, JM; Moreau, S; Puppo, A, 1995
)
0.29
" The bioavailability of the compounds was enhanced in the following order on both oral and intraperitoneal administration: VO(6mpa)2 > VO(pic)2 > VS."( Pharmacokinetic study on gastrointestinal absorption of insulinomimetic vanadyl complexes in rats by ESR spectroscopy.
Fugono, J; Sakurai, H; Yasui, H, 2001
)
0.31
" Pharmacokinetic analysis demonstrated that these capsules enhance the bioavailability of pharmacologically active vanadyl species."( Pharmacokinetic study and trial for preparation of enteric-coated capsule containing insulinomimetic vanadyl compounds: implications for clinical use.
Fugono, J; Sakurai, H; Yasui, H, 2004
)
0.32
" We compared the ability of bis(maltolato)oxovanadium(IV) (BMOV), an orally bioavailable organo-vanadium compound, and rosiglitazone maleate (RSG), a known insulin sensitizer, to prevent development of diabetes in Zucker diabetic fatty (ZDF) rats."( A nonspecific phosphotyrosine phosphatase inhibitor, bis(maltolato)oxovanadium(IV), improves glucose tolerance and prevents diabetes in Zucker diabetic fatty rats.
Davis, MG; Downs, TR; Gerwe, GS; Kasibhatla, B; Lange, JS; Peters, KG; Winter, CL, 2005
)
0.33
" Overall, the results obtained indicate that the genotoxic activity of pentavalent vanadium is expressed in vivo only following high dose exposure, possibly as a consequence of the poor bioavailability of the element."( Assessment of the in vivo genotoxicity of vanadate: analysis of micronuclei and DNA damage induced in mice by oral exposure.
Cordelli, E; Crebelli, R; Leopardi, P; Siniscalchi, E; Veschetti, E; Villani, P, 2005
)
0.33
" It has been shown that elements are poorly absorbed in their inorganic forms and required high doses which have been associated with undesirable side effects."( Syntheses of vanadyl and zinc(II) complexes of 1-hydroxy-4,5,6-substituted 2(1H)-pyrimidinones and their insulin-mimetic activities.
Adachi, Y; Katoh, A; Saito, R; Sakurai, H; Wakasugi, K; Yamaguchi, M; Yoshikawa, Y, 2006
)
0.33
" It is unknown if the tea alters the bioavailability of vanadate."( Short-term bioaccumulation of vanadium when ingested with a tea decoction in streptozotocin-induced diabetic rats.
Aguilar, F; Clark, TA; Edel, AL; Ganguly, PK; Heyliger, CE; Kopilas, M; Pierce, GN, 2006
)
0.33
" As an effort to develop novel metal-based selective hypoxia-cytotoxins and to improve bioavailability and pharmacological and toxicological properties of aminoquinoxaline carbonitrile N-dioxides bioreductive prodrugs, the new complex and VO(L)2 complexes, with L=3-amino-6(7)-bromoquinoxaline-2-carbonitrile N1,N4-dioxide (L2) and 3-amino-6(7)-methylquinoxaline-2-carbonitrile N1,N4-dioxide (L3), were subjected to cytotoxic evaluation in V79 cells in hypoxic and aerobic conditions."( Selective hypoxia-cytotoxins based on vanadyl complexes with 3-aminoquinoxaline-2-carbonitrile-N1,N4-dioxide derivatives.
Azqueta, A; Cerecetto, H; Costa-Filho, AJ; de Cerain, AL; Gambino, D; González, M; Laura Lavaggi, M; Monge, A; Noblía, P; Parajón-Costa, B; Torre, MH; Vieites, M, 2006
)
0.33
"The uptake and bioavailability of lead (Pb) in soil-plant systems remain poorly understood."( Organic acids enhance the uptake of lead by wheat roots.
Han, F; Liu, T; Shan, X; van Genuchten, MT; Wang, H; Wen, B; Xie, Y; Zhang, S, 2007
)
0.34
" However, it reduced the elevated serum SSAO activity, decreased the accumulation of advanced-glycation end products and increased the bioavailability of nitric oxide in diabetic animals, similarly to insulin."( Studies on the insulinomimetic effects of benzylamine, exogenous substrate of semicarbazide-sensitive amine oxidase enzyme in streptozotocin induced diabetic rats.
Halász, AS; Kocsis, E; Magyar, K; Pálfi, M; Soltész, Z; Szökö, E; Tábi, T; Tóth, M, 2007
)
0.34
" The average absolute bioavailability for intragastric administration at a single dose of 3, 6 and 12 mgV/kg was 28."( The anti-diabetic effects and pharmacokinetic profiles of bis(maltolato)oxovanadium in non-diabetic and diabetic rats.
Chen, GH; Lu, WL; Zhang, Q; Zhang, SQ; Zhong, XY, 2008
)
0.35
" These bis-ligand oxovanadium(IV) (VOL(2)) compounds have a clear advantage over inorganic vanadyl sulfate in terms of bioavailability and pharmaceutical efficacy."( Vanadium treatment of type 2 diabetes: a view to the future.
LeBel, C; Lichter, J; McNeill, JH; Orvig, C; Scaife, MC; Thompson, KH, 2009
)
0.35
" Both the DNA binding constants and photo nuclease activities of the complexes follow the order 2 (tmp) > 3 (dpq) > 1 (phen), demonstrating the importance of the binding affinity to biomolecules, which improves the bioavailability of reactive oxygen species."( Oxovanadium(IV) based hypocrellin B complexes with enhanced photodynamic activity.
Hou, YJ; Lei, WH; Sun, Y; Wang, XS; Zhang, BW; Zheng, Y; Zhou, QX, 2012
)
0.38
" Sequential gastric and intestinal digestion in the absence of food converted A, B and D to poorly absorbed tetrahedral vanadates, while C formed five- or six-coordinate V(V) species where the maltolato ligands were likely to be partially retained."( Reactivity-activity relationships of oral anti-diabetic vanadium complexes in gastrointestinal media: an X-ray absorption spectroscopic study.
Aitken, JB; Glover, CJ; Johannessen, B; Kremer, LE; Lay, PA; Levina, A; McLeod, AI, 2014
)
0.4
" The aim of this study was to assess the vanadium bioavailability in BF slags when applied to soil."( Vanadium bioavailability in soils amended with blast furnace slag.
Baken, S; Cubadda, F; Gustafsson, JP; Larsson, MA; Smolders, E, 2015
)
0.42
" Interestingly, VC-IV did not alter the bioavailability and renal accumulation of CDDP in mice."( Ameliorative effect of an oxovanadium (IV) complex against oxidative stress and nephrotoxicity induced by cisplatin.
Basu, A; Bhattacharjee, A; Bhattacharya, S; Hajra, S; Samanta, A, 2017
)
0.46
"Hydroxypyrone derivatives have a good bioavailability in rats and mice and have been used in drug development."( Oxovanadium(IV) Coordination Compounds with Kojic Acid Derivatives in Aqueous Solution.
Alladio, E; Berto, S; Bono, A; Cappai, R; Daniele, PG; Lachowicz, JI; Laurenti, E; Nurchi, VM; Sgarlata, C; Valora, G, 2019
)
0.51
" Extracellular polymeric substances could bind V(V) and improve the bioavailability of PHE."( Microbial vanadate reduction coupled to co-metabolic phenanthrene biodegradation in groundwater.
Cheng, Y; Peng, K; Shi, J; Zhang, B, 2020
)
0.56
" In this study we sourced specifically hydrophobic forms of oxidovanadium complexes with the explicit aim of demonstrating liposomal encapsulation, bioavailability in cultured neuroblastoma cells, and effective cytotoxic or differentiating activity."( The liposomal delivery of hydrophobic oxidovanadium complexes imparts highly effective cytotoxicity and differentiating capacity in neuroblastoma tumour cells.
Eaton, S; Hart, SL; Irving, E; Lehtonen, A; Maeshima, R; Stoker, AW; Tagalakis, AD, 2020
)
0.56
"The therapeutic application of vanadium compounds is plagued by their poor bioavailability and potential adverse effects."( Surface Engineering Promoted Insulin-Sensitizing Activities of Sub-Nanoscale Vanadate Clusters through Regulated Pharmacokinetics and Bioavailability.
Chen, K; Liu, S; Yin, P; Zhu, W, 2022
)
0.72

Dosage Studied

ExcerptRelevanceReference
" The complexes shift the dose-response curve to the left."( Hydrophobic carriers of vanadyl ions augment the insulinomimetic actions of vanadyl ions in rat adipocytes.
Lazar, R; Libman, J; Shanzer, A; Shechter, Y; Shisheva, A, 1992
)
0.28
" Dose-response experiments revealed a close correlation between the extent of protein synthesis inhibition and the level of activation of pp70-S6 kinase activity."( Distinct mechanisms for the activation of the RSK kinases/MAP2 kinase/pp90rsk and pp70-S6 kinase signaling systems are indicated by inhibition of protein synthesis.
Alcorta, DA; Blenis, J; Chung, J; Erikson, E; Erikson, RL, 1991
)
0.28
" Two determination scales of the reducers were elaborated and the isoniazide hydrazide from tablets was dosed with satisfactory results."( [The photocolorimetric determination of reducing agents using sodium metavanadate as reagent].
Dima, F; Dorneanu, V; Miftode, M; Stan, M; Vasilescu, M,
)
0.13
" The La dose-response curves for H influx and for Ca efflux were similar [50% inhibitory concentration (IC50) = approximately 5 microM] in intact red blood cells."( Proton fluxes associated with the Ca pump in human red blood cells.
Milanick, MA, 1990
)
0.28
" In the presence of 3 mM H2O2, both protein tyrosine phosphorylation and InsP formation are highly correlated and manifest an identical dose-response relationship for vanadate."( A combination of H2O2 and vanadate concomitantly stimulates protein tyrosine phosphorylation and polyphosphoinositide breakdown in different cell lines.
Sagi-Eisenberg, R; Zick, Y, 1990
)
0.28
" Finally, the insulin dosage required to maintain a nonglycosuric state in spontaneously diabetic (BB) rats was reduced in the presence of vanadyl."( Enhanced in vivo sensitivity of vanadyl-treated diabetic rats to insulin.
Cros, GH; McNeill, JH; Mongold, JJ; Ramanadham, S; Serrano, JJ, 1990
)
0.28
"A daily dosage of vanadate (0."( Time and dose-response study of the effects of vanadate in rats: changes in blood cells, serum enzymes, protein, cholesterol, glucose, calcium, and inorganic phosphate.
al-Bayati, MA; Giri, SN; Raabe, OG,
)
0.13
" The dose-response relationships of this effect were measured by equilibrating cell aliquots with various Ca2+-EGTA buffers, preparing membrane vesicles (in the absence of Ca2+ ions), and assaying them for amiloride-sensitive Na+ permeability."( Ca2+-induced down-regulation of Na+ channels in toad bladder epithelium.
Asher, C; Garty, H, 1986
)
0.27
" The link between phospholipase C activation and these early events of the mitogenic response is demonstrated by the similarity of all dose-response curves for NaF and AlCl3 and by the common sensitivity of the four events to pertussis toxin."( Coupling between phosphoinositide breakdown and early mitogenic events in fibroblasts. Studies with fluoroaluminate, vanadate, and pertussis toxin.
Chambard, JC; Paris, S; Pouysségur, J, 1987
)
0.27
" 24 h after the vanadium injections to different groups of rats at two dosage levels, 30 and 100 mumol/kg."( The effect of chelating agents on vanadium distribution in the rat body and on uptake by human erythrocytes.
Aaseth, J; Alexander, J; Hansen, TV, 1982
)
0.26
" The initial daily dosage of 100 mg elemental vanadium was increased by 50 mg at 2-d intervals for an assessment not only of the toxic effects, but also to determined the amount that caused a decline in feed intake to 25% of that of control animals."( Vanadium metabolism in sheep. I. Comparative and acute toxicity of vanadium compounds in sheep.
Ammerman, CB; Hansard, SL; Henry, PR; Simpson, CF, 1982
)
0.26
" An oral dose-response curve showed that BMOV was 2 to 3 times as potent as vanadyl sulfate."( Comparison of the glucose-lowering properties of vanadyl sulfate and bis(maltolato)oxovanadium(IV) following acute and chronic administration.
McNeill, JH; Orvig, C; Yuen, VG, 1995
)
0.29
" Tiron effectiveness was assessed at dosage levels of 0, 250, 500, and 1,000 mg/kg."( Prevention by Tiron (sodium 4,5-dihydroxybenzene-1,3-disulfonate) of vanadate-induced developmental toxicity in mice.
Bosque, MA; Corbella, J; Domingo, JL; Luna, M, 1993
)
0.29
" Addition of vanadate per se induces proliferation of only a very limited amount of cells, but results in a shift of the dose-response curves for other growth factors to lower concentrations."( Orthovanadate both mimics and antagonizes the transforming growth factor beta action on normal rat kidney cells.
Rijksen, G; Van Zoelen, EJ; Völler, MC, 1993
)
0.29
" The dose-response curve showed that vanadate decreased the specific D-glucose uptake by a maximum of 70% compared with a control preparation."( Effect of vanadate on glucose transporter (GLUT4) intrinsic activity in skeletal muscle plasma membrane giant vesicles.
Kristiansen, S; Richter, EA; Youn, J, 1996
)
0.29
" Thus, orthovanadate could possibly be used as a growth factor for bone, if administered at the critical dosage at the proper stage of the life cycle of the osteoblast."( Enhancement by sodium orthovanadate of the formation and mineralization of bone nodules by chick osteoblasts in vitro.
Henderson, JS; Johnson, RB, 1997
)
0.3
" Both PIA and PGE1 (which downregulate Gi) decreased the maximal responsiveness of the cells to insulin by approximately 30% and caused a rightward shift in the dose-response curve."( Insulin resistance in adipocytes after downregulation of Gi subtypes.
Belt, SE; Green, A; Walters, DJ, 1997
)
0.3
" Dose-response curves were non-monotonic passing a maximum at low dosages."( Low-molecular-weight hormonal factors that affect head formation in Hydra.
Bartsch, C; Bartsch, H; Bayer, E; Maidonis, I; Müller, WA, 1998
)
0.3
" We report here the speed, reversibility and dose-response of PMCA inhibition by vanadate in intact human red cells."( Kinetics of inhibition of the plasma membrane calcium pump by vanadate in intact human red cells.
Lew, VL; Tiffert, T, 2001
)
0.31
" On tumoral cells, TreVO caused a weak stimulation of growth at 5 microM but it inhibited cell proliferation in a dose-response manner between 50 and 100 microM."( Synthesis of a new vanadyl(IV) complex with trehalose (TreVO): insulin-mimetic activities in osteoblast-like cells in culture.
Barrio, DA; Cortizo, AM; Etcheverry, SB; Williams, PA, 2003
)
0.32
" Insulinemia, at the onset of the treatment as well as immediately after its cessation showed a drop in the treatment groups, proportionally to the dosage of vanadium, but later increased slowly and continuously until the end of the experiment."( The influence of sodium metavanadate on the process of diabetogenesis in BB rats.
Buligescu, S; Cheta, D; Coman, A; Constantin, C; Enache, M; Gutu, D; Hassanain, M; Iordachescu, D; Negru, R; Nicolaie, T; Orasanu, G; Panaite, C; Tica, V; Timofte, D,
)
0.13
" The dose-response was described best by a linear equation."( Orthovanadate increased the frequency of aneuploid mouse sperm without micronucleus induction in mouse bone marrow erythrocytes at the same dose level.
Adler, ID; Attia, SM; Badary, OA; de Angelis, MH; Hamada, FM, 2005
)
0.33
" Dose-response curves demonstrated that as little as 1pM 1,25(OH)2D3 significantly inhibited chemotaxis enhancement."( Selective inhibition of the C5a chemotactic cofactor function of the vitamin D binding protein by 1,25(OH)2 vitamin D3.
DiMartino, SJ; Kew, RR; Shah, AB; Trujillo, G, 2006
)
0.33
" The methods are applicable to the assay of the drug under investigation in different dosage forms and the results are in good agreement with those obtained by the official methods."( Sensitive spectrophotometric methods for quantitative determination of chlorprothixene in pharmaceutical dosage form.
Misiuk, W, 2006
)
0.33
"5 ppm vanadium is potentially and optimally effective, as derived from dose-response studies, in limiting early molecular events and preneoplastic lesions, thereby modulating the initiation stage of hepatocarcinogenesis."( Carcinogen-induced early molecular events and its implication in the initiation of chemical hepatocarcinogenesis in rats: chemopreventive role of vanadium on this process.
Chakraborty, T; Chatterjee, A; Chatterjee, M; Dhachinamoorthi, D; Kumar P, A; Rana, A, 2007
)
0.34
" In conclusion, at the present dosing levels and administration routes, BMOV was effective in lowering plasma glucose levels in diabetic rats."( The anti-diabetic effects and pharmacokinetic profiles of bis(maltolato)oxovanadium in non-diabetic and diabetic rats.
Chen, GH; Lu, WL; Zhang, Q; Zhang, SQ; Zhong, XY, 2008
)
0.35
" Chrysin and VOchrys caused an inhibition of cell proliferation in MC3T3E1 normal osteoblasts and UMR106 tumor cells in a dose-response manner, with a greater effect in the latter cell line."( Role of oxidative stress in the antitumoral action of a new vanadyl(IV) complex with the flavonoid chrysin in two osteoblast cell lines: relationship with the radical scavenger activity.
Etcheverry, SB; Ferrer, EG; Lezama, L; Naso, L; Rojo, T; Williams, P, 2010
)
0.36
" VO(oda) altered lysosomal and mitochondria metabolisms (neutral red and MTT bioassays) in a dose-response manner from 10 μM (P < 0."( Cyto- and genotoxicity of a vanadyl(IV) complex with oxodiacetate in human colon adenocarcinoma (Caco-2) cells: potential use in cancer therapy.
Butenko, N; Cavaco, I; Di Virgilio, AL; Etcheverry, SB; Muglia, CI; Reigosa, MA; Rivadeneira, J, 2011
)
0.37
" The degradation of 2-CP was affected by solution pH, light intensity, photocatalyst dosage and 2-CP initial concentration."( InVO4/TiO2 composite for visible-light photocatalytic degradation of 2-chlorophenol in wastewater.
Barakat, MA; Kuhn, JN; Pettit, SL; Rashid, J,
)
0.13
" The metforminium decavanadate (H2Metf)3[V10O28]·8H2O, abbreviated as Metf-V10O28, was shown to have pharmacological potential as a hypoglycemic, lipid-lowering and metabolic regulator, since the resulting compound made of the two components with antidiabetic activities, reduces both dosage and time of administration (twice a week)."( Hypoglycemic, lipid-lowering and metabolic regulation activities of metforminium decavanadate (H2Metf)3 [V10O28]·8H2O using hypercaloric-induced carbohydrate and lipid deregulation in Wistar rats as biological model.
Brambila-Colombres, E; Flores-Hernández, JÁ; González-Vergara, E; Pérez-Benítez, A; Sánchez-Lara, E; Sánchez-Lombardo, I; Sarmiento-Ortega, VE; Treviño, S, 2015
)
0.42
" Administration of SMV was done intraperitoneally daily for 14 consecutive days at a dosage of 3 mg/kg body weight."( Reproductive Hormones Imbalance, Germ Cell Apoptosis, Abnormal Sperm Morphophenotypes and Ultrastructural Changes in Testis of African Giant Rats (Cricetomys gambianus) Exposed to Sodium Metavanadate Intoxication.
Adikpe, AO; Emikpe, BO; Nafady, AAHM; Olopade, JO; Oyelowo, FO; Usende, IL, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
EC 3.1.3.1 (alkaline phosphatase) inhibitorAn EC 3.1.3.* (phosphoric monoester hydrolase) inhibitor that interferes with the action of alkaline phosphatase (EC 3.1.3.1).
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitorAny EC 3.1.3.* (phosphoric monoester hydrolase) inhibitor that interferes with the action of phosphoprotein phosphatase (EC 3.1.3.16).
EC 3.1.3.41 (4-nitrophenylphosphatase) inhibitorAn EC 3.1.3.* (phosphoric monoester hydrolase) inhibitor that interferes with the action of 4-nitrophenylphosphatase (EC 3.1.3.41).
EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitorAn EC 3.1.3.* (phosphoric monoester hydrolase) inhibitor which interferes with the activity of the enzyme protein tyrosine phosphatases (PTPs), EC 3.1.3.48, involved in the removal of phosphate groups from phosphorylated tyrosine residues on proteins.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
vanadium oxoanion
trivalent inorganic anionAny inorganic anion with a valency of three.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (17)

PathwayProteinsCompounds
superpathway of glycolysis and the Entner-Doudoroff pathway2358
superpathway of glycolysis, pyruvate dehydrogenase, TCA, and glyoxylate bypass3989
CMP-N-acetylneuraminate biosynthesis I (eukaryotes)738
pyrimidine deoxyribonucleotides de novo biosynthesis I3034
D-sorbitol biosynthesis I115
coenzyme M biosynthesis I528
phytate degradation I021
superpathway of N-acetylneuraminate degradation3979
starch degradation III115
superpathway of hexitol degradation (bacteria)2960
superpathway of CMP-sialic acids biosynthesis1460
glycolysis II (from fructose 6-phosphate)2149
glycolysis I (from glucose 6-phosphate)3751
UDP-u03B1-D-glucose biosynthesis I1424
Entner-Doudoroff pathway I1639
superpathway of pyrimidine deoxyribonucleotides de novo biosynthesis4662
NAD salvage pathway III (to nicotinamide riboside)213

Protein Targets (5)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Receptor-type tyrosine-protein phosphatase FHomo sapiens (human)IC50 (µMol)22.56331.30002.66604.2300AID1800516
Tyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)IC50 (µMol)22.56330.70004.58049.4500AID1800516
Tyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)IC50 (µMol)16.92880.00053.49849.7600AID1800516; AID1803323
Tyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)IC50 (µMol)22.56330.29002.20754.2300AID1800516
Tyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)IC50 (µMol)22.56330.31804.00429.6000AID1800516
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (141)

Processvia Protein(s)Taxonomy
cell adhesionReceptor-type tyrosine-protein phosphatase FHomo sapiens (human)
cell surface receptor protein tyrosine phosphatase signaling pathwayReceptor-type tyrosine-protein phosphatase FHomo sapiens (human)
cell migrationReceptor-type tyrosine-protein phosphatase FHomo sapiens (human)
neuron projection regenerationReceptor-type tyrosine-protein phosphatase FHomo sapiens (human)
peptidyl-tyrosine dephosphorylationReceptor-type tyrosine-protein phosphatase FHomo sapiens (human)
regulation of axon regenerationReceptor-type tyrosine-protein phosphatase FHomo sapiens (human)
synaptic membrane adhesionReceptor-type tyrosine-protein phosphatase FHomo sapiens (human)
negative regulation of receptor bindingReceptor-type tyrosine-protein phosphatase FHomo sapiens (human)
negative regulation of transcription by RNA polymerase IITyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of cell population proliferationTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of tumor necrosis factor-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of lipid storageTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
B cell differentiationTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
T cell differentiationTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
erythrocyte differentiationTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
peptidyl-tyrosine dephosphorylationTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
insulin receptor recyclingTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of epidermal growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of tyrosine phosphorylation of STAT proteinTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
glucose homeostasisTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of macrophage differentiationTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
positive regulation of gluconeogenesisTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of inflammatory responseTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of T cell receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of chemotaxisTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
regulation of type II interferon-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of type II interferon-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of type I interferon-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of interleukin-6-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
regulation of hepatocyte growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of interleukin-2-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of interleukin-4-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of macrophage colony-stimulating factor signaling pathwayTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of positive thymic T cell selectionTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
positive regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathwayTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
positive regulation of PERK-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of platelet-derived growth factor receptor-beta signaling pathwayTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of receptor signaling pathway via JAK-STATTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
positive regulation of JUN kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein dephosphorylationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of signal transductionTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of signal transductionTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
actin cytoskeleton organizationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of endocytosisTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of vascular endothelial growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulum unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of intracellular protein transportTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cellular response to unfolded proteinTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
peptidyl-tyrosine dephosphorylationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
platelet-derived growth factor receptor-beta signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
IRE1-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor recyclingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of MAP kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of type I interferon-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
growth hormone receptor signaling pathway via JAK-STATTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of protein tyrosine kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of hepatocyte growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of IRE1-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of PERK-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
peptidyl-tyrosine dephosphorylation involved in inactivation of protein kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of receptor catabolic processTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
MAPK cascadeTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
hematopoietic progenitor cell differentiationTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
negative regulation of humoral immune response mediated by circulating immunoglobulinTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
protein dephosphorylationTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
G protein-coupled receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
positive regulation of cell population proliferationTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
negative regulation of cell population proliferationTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
negative regulation of angiogenesisTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
peptidyl-tyrosine phosphorylationTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
cytokine-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
cell differentiationTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
platelet formationTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
T cell costimulationTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
negative regulation of interleukin-6 productionTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
negative regulation of tumor necrosis factor productionTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
negative regulation of mast cell activation involved in immune responseTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
positive regulation of cell adhesion mediated by integrinTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
peptidyl-tyrosine dephosphorylationTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
megakaryocyte developmentTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
T cell proliferationTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
negative regulation of T cell proliferationTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
natural killer cell mediated cytotoxicityTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
regulation of apoptotic processTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
negative regulation of MAPK cascadeTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
regulation of B cell differentiationTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
negative regulation of peptidyl-tyrosine phosphorylationTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
T cell receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
B cell receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
negative regulation of T cell receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
regulation of release of sequestered calcium ion into cytosolTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
regulation of type I interferon-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
regulation of ERK1 and ERK2 cascadeTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
platelet aggregationTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
negative regulation of inflammatory response to woundingTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
epididymis developmentTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
regulation of G1/S transition of mitotic cell cycleTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
intracellular signal transductionTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
mitotic cell cycleTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
DNA damage checkpoint signalingTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
protein dephosphorylationTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
triglyceride metabolic processTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
epidermal growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
integrin-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
axonogenesisTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
brain developmentTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
heart developmentTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
fibroblast growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
hormone-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
cytokine-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
cerebellar cortex formationTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
platelet formationTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
T cell costimulationTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
negative regulation of chondrocyte differentiationTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
negative regulation of type I interferon productionTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
microvillus organizationTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
positive regulation of interferon-beta productionTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
positive regulation of interleukin-6 productionTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
positive regulation of tumor necrosis factor productionTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
regulation of cell adhesion mediated by integrinTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
negative regulation of cell adhesion mediated by integrinTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
multicellular organism growthTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
organ growthTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
peptidyl-tyrosine dephosphorylationTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
megakaryocyte developmentTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
atrioventricular canal developmentTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
ERBB signaling pathwayTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
hormone metabolic processTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
glucose homeostasisTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
regulation of protein-containing complex assemblyTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
positive regulation of ossificationTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
positive regulation of mitotic cell cycleTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
positive regulation of glucose importTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
positive regulation of insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
negative regulation of insulin secretionTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
regulation of protein export from nucleusTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
positive regulation of hormone secretionTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
platelet-derived growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
neurotrophin TRK receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
ephrin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
multicellular organismal reproductive processTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
genitalia developmentTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
inner ear developmentTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
homeostasis of number of cells within a tissueTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
negative regulation of cortisol secretionTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
Bergmann glial cell differentiationTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
negative regulation of growth hormone secretionTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
face morphogenesisTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
regulation of type I interferon-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
intestinal epithelial cell migrationTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
cellular response to epidermal growth factor stimulusTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (29)

Processvia Protein(s)Taxonomy
protein tyrosine phosphatase activityReceptor-type tyrosine-protein phosphatase FHomo sapiens (human)
transmembrane receptor protein tyrosine phosphatase activityReceptor-type tyrosine-protein phosphatase FHomo sapiens (human)
heparin bindingReceptor-type tyrosine-protein phosphatase FHomo sapiens (human)
chondroitin sulfate proteoglycan bindingReceptor-type tyrosine-protein phosphatase FHomo sapiens (human)
protein-containing complex bindingReceptor-type tyrosine-protein phosphatase FHomo sapiens (human)
cell adhesion molecule bindingReceptor-type tyrosine-protein phosphatase FHomo sapiens (human)
protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
integrin bindingTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
protein bindingTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
protein kinase bindingTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
syntaxin bindingTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
receptor tyrosine kinase bindingTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
STAT family protein bindingTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
non-membrane spanning protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
RNA bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
zinc ion bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
enzyme bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein kinase bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
receptor tyrosine kinase bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cadherin bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
ephrin receptor bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein phosphatase 2A bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
non-membrane spanning protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
phosphotyrosine residue bindingTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
transmembrane receptor protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
protein bindingTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
SH3 domain bindingTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
protein kinase bindingTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
SH2 domain bindingTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
cell adhesion molecule bindingTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
phosphorylation-dependent protein bindingTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
non-membrane spanning protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
phosphotyrosine residue bindingTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
phosphoprotein phosphatase activityTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
non-membrane spanning protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
insulin receptor bindingTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
protein bindingTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
protein kinase bindingTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
signaling receptor complex adaptor activityTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
cadherin bindingTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
cell adhesion molecule bindingTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
peptide hormone receptor bindingTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
molecular adaptor activityTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
protein tyrosine kinase bindingTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
receptor tyrosine kinase bindingTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (24)

Processvia Protein(s)Taxonomy
plasma membraneReceptor-type tyrosine-protein phosphatase FHomo sapiens (human)
neuron projectionReceptor-type tyrosine-protein phosphatase FHomo sapiens (human)
neuronal cell bodyReceptor-type tyrosine-protein phosphatase FHomo sapiens (human)
extracellular exosomeReceptor-type tyrosine-protein phosphatase FHomo sapiens (human)
plasma membraneTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
nucleoplasmTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
endoplasmic reticulumTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
endoplasmic reticulum-Golgi intermediate compartmentTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
cytosolTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
endosome lumenTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
nucleusTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
plasma membraneTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
mitochondrial matrixTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
early endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulumTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytosolTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
mitochondrial cristaTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endosome lumenTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
sorting endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmic side of endoplasmic reticulum membraneTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein-containing complexTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulumTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
early endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
plasma membraneTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
extracellular regionTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
nucleusTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
nucleoplasmTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
nucleolusTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
cytosolTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
cell-cell junctionTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
membraneTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
specific granule lumenTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
extracellular exosomeTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
tertiary granule lumenTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
protein-containing complexTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
alpha-beta T cell receptor complexTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
nucleusTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
nucleoplasmTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
cytosolTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
protein-containing complexTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID1800516pNPP assay from Article 10.1016/j.bmcl.2014.03.015: \\Synthesis and biological evaluation of novel bis-aromatic amides as novel PTP1B inhibitors.\\2014Bioorganic & medicinal chemistry letters, Apr-15, Volume: 24, Issue:8
Synthesis and biological evaluation of novel bis-aromatic amides as novel PTP1B inhibitors.
AID1803323PTP1B Activity Assay from Article 10.3109/14756366.2012.715286: \\In vitro effects of cinnamic acid derivatives on protein tyrosine phosphatase 1B.\\2013Journal of enzyme inhibition and medicinal chemistry, Oct, Volume: 28, Issue:5
In vitro effects of cinnamic acid derivatives on protein tyrosine phosphatase 1B.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5,001)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990906 (18.12)18.7374
1990's1821 (36.41)18.2507
2000's1403 (28.05)29.6817
2010's719 (14.38)24.3611
2020's152 (3.04)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials7 (0.13%)5.53%
Reviews101 (1.94%)6.00%
Case Studies5 (0.10%)4.05%
Observational1 (0.02%)0.25%
Other5,086 (97.81%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]